2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
Dalteparin
11
apixaban
10
Tinzaparin
5
Enoxaparin
5
Rivaroxaban
4
Heparin, Low-Molecular-Weight
3
Dabigatran
3
edoxaban
2
bemiparin
2
abelacimab
2
Warfarin
2
MAA868
2
Fondaparinux
2
perflutren
1
isoquercitrin
1
enoxaparin sodium
1
Sulfur Hexafluoride
1
Rosuvastatin Calcium
1
Phenprocoumon
1
Nephrectomy
1
Nadroparin
1
Hospitals
1
Heparin
1
Fluorodeoxyglucose F18
1
Educational Status
1
Drug Delivery Systems
1
Deoxyribonucleases
1
Aspirin
1
Acetylcysteine
1
Acenocoumarol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pulmonary Embolism
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled